Takeda Pharmaceutical Company Limited (NYSE:TAK) saw an upside of 1.05% to close Monday at $15.37 after adding $0.16 on the day. The 5-day average trading volume is 3,536,760 shares of the company’s common stock. It has gained $15.40 in the past week and touched a new high 3 times within the past 5 days. An average of 3,231,885 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,278,216.
TAK’s 1-month performance is -0.71% or -$0.11 on its low of $14.92 reached on 08/01/23. The company’s shares have touched a 52-week low of $12.28 and high of $17.15, with the stock’s rally to the 52-week high happening on 04/06/23. YTD, TAK has lost -1.47% or -$0.23 and has reached a new high 11 times. However, the current price is down -10.38% from the 52-week high price.
Valuation Metrics
TAK stock has a beta of 0.64. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.69 while the price-to-book (PB) in the most recent quarter is 0.98.
Takeda Pharmaceutical Company Limited’s quick ratio for the recent period was 0.60, with the current ratio over the same period at 1.00. In terms of profitability, the gross margin trailing 12 months is 69.10%. The firm’s gross profit as reported stood at $20.6 billion against revenue of $29.8 billion.
Earnings Surprise
Takeda Pharmaceutical Company Limited’s cash and short-term investments amounted to $223.52 million against total debt of $5.24 trillion. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 23.27% to $2.2 billion, while revenue of $0.0 was 100.0% off the previous quarter. EBITDA for the quarter stood at more than $2.48 billion. TAK stock balance sheet for the recent quarter shows that total liabilities totaled 57.46 billion, with total debt at $5.24 trillion.
Let’s look briefly at Takeda Pharmaceutical Company Limited (TAK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 50.73% to suggest the stock is trending Neutral, with historical volatility in this time period at 14.47%.
The stock’s 5-day moving average is $15.20, reflecting a +0.72% or $0.11 change from its current price. TAK is currently trading -1.09% above its 20-day SMA, -4.42% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -5.42% and SMA200 by+20.93%.
Stochastic %K and %D was 36.70% and 29.34% and the average true range (ATR) pointed at 0.20. The RSI (14) points at 46.72%, while the 14-day stochastic is at 50.56% with the period’s ATR at 0.19. The stock’s 9-day MACD Oscillator is pointing at -0.04 and -0.10 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Takeda Pharmaceutical Company Limited (NYSE: TAK), BofA Securities upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for TAK stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate TAK as a “sell,”, while 12 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 6 have offered a “buy” rating.
What is TAK’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.80 and a high of $20.67, with their median price target at $16.75. Looking at these predictions, the average price target given by analysts is for Takeda Pharmaceutical Company Limited (TAK) stock is $16.68.
